Understand the source comparison
IGF-1 LR3 vs IGF1 LR3 — Same Peptide, Different Names
The confusion around what's the difference between IGF-1 LR3 and IGF1 LR3 comes from notation inconsistency across suppliers, publications, and research databases. Not from any actual structural or functional difference. Both terms describe the exact same 83-a
No winner is assigned.
This page preserves a source comparison for education. It does not add a rating, recommendation or clinical judgment.
- The confusion around what's the difference between IGF-1 LR3 and IGF1 LR3 comes from notation inconsistency across suppliers, publications, and research databases. Not from any actual structural or functional difference. Both terms describe the exact same 83-amino-acid peptide: Long R3 Insulin-Like Growth Factor-1. The hyphen in 'IGF-1' versus the absence of a hyphen in 'IGF1' is a stylistic choice, not a biochemical distinction. Some manufacturers hyphenate the abbreviation, others don't. The peptide itself remains unchanged.
- We've worked with research-grade peptides for years, and this naming discrepancy creates more confusion than it should. The important part isn't the hyphen. It's understanding what 'LR3' means and why that modification matters for experimental protocols.
- What's the difference between IGF-1 LR3 and IGF1 LR3?
- There is no difference between IGF-1 LR3 and IGF1 LR3. They are the same peptide. Both names refer to Long R3 Insulin-Like Growth Factor-1, a synthetic analogue of natural IGF-1 with an extended half-life (20–30 hours versus 10–12 minutes for native IGF-1) due to structural modifications at the N-terminus. The hyphen is a notational preference, not a functional distinction. Suppliers and researchers use both forms interchangeably.
- The reason both names exist is straightforward: scientific naming conventions allow flexibility in abbreviation formatting. 'IGF-1' follows hyphenated nomenclature standard in endocrinology literature, while 'IGF1' reflects condensed notation common in peptide synthesis and commercial catalogs. Neither is wrong. Both point to the same compound: a recombinant peptide engineered to resist degradation by IGF-binding proteins (IGFBPs) and maintain prolonged activity in biological systems.
- This article covers what the 'LR3' modification actually does, why the extended half-life matters for research applications, how IGF-1 LR3 differs from native IGF-1, and what researchers should verify when sourcing this peptide regardless of how the supplier writes the name.